top of page

Biological Modeling


Our vast tumor organoid repository enables new possibilities for therapy selection and drug discovery


We aim to transform therapy selection and drug discovery and development by building the world’s largest library of human ex vivo tumor-derived organoids* that are characterized by molecular features and associated clinical outcomes in robust, reproducible 3D models.

Contact Us

Our Solutions

Custom organoid screening models
Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.

  • Tumor Origin: Pan-Cancer, client-selected indications

  • Molecular Profiling: Client-selected molecular alterations, mutations, CNVs, fusions, etc.

Predefined organoid screening models
Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.

  • PanTumor 60™: primary and metastatic tumors

    • Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver

    • Molecular Profiling: STAR Health Network xT molecular profiles and whole transcriptome

  • PanTumor IO™: primary and metastatic tumors with allogeneic MHC-matched PBMCs

    • Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver

    • Molecular Profiling: STAR Health Network xT molecular profiles and whole transcriptome, four digit HLA genotyping

    • Designed to screen cell engagers and adoptive cell therapeutics

Single cell RNA sequencing
Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response

Spatial transcriptomics
Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response


  • Breast

  • Colon

  • Endometrial Adeno

  • Gastric

  • Head + Neck SCC

  • Liver HCC

  • NSCLC Adeno


  • Ovarian

  • Pancreatic

Our solutions can be broadly applied to preclinical and post-approval strategies

  • Target validation

  • Indication selection

  • Phenotypic (clinical) + Exploratory (MOA) studies

  • Exploration of rare patient mutations and alterations

  • Combination identification

  • Signature development for responder enrichment

  • Immune cell activation

  • Label expansion plans

Our Differentiators

commercially available biological models

Full Characterization
of tumor organoids with STAR Health Network xT solid tumor comprehensive profiling

3D confocal imaging assays with AI analytics on every tumor organoid drug sensitivity screen

Innovative Pipeline
of automation-driven assays enable expedited experimental processes

How It Works

Individual human ex vivo tumor-derived organoids* are screened in STAR Health Network’ high-throughput environment. STAR Health Network organoids are NGS-qualified and have been pre-screened against a panel of chemotherapies and small molecule therapeutics. Our 3D models serve as the basis for drug screening efforts for drug discovery and development.

01 Organoids are grown in proprietary chemically defined conditions from core biopsies or surgical resections.

02 Organoid histology is verified by board-certified medical pathologists.

03 Full transcriptomic profiles are generated by RNA sequencing.

04 Tumor mutation recapitulation is assessed by overlap of somatic variants between tumor and tumor organoids via the STAR Health Network xT 648 gene panel.

05 Organoids are phenotyped via high content assays, which are then analyzed via automated machine vision algorithms employing state-of-the-art computer vision models to segment organoids, quantify infiltrating immune cells, and predict drug efficacies along with other clinical endpoints as desired.

*Specimens collected under IRB-approved research protocols

bottom of page